Asia-Pacific Pneumococcal Disease Control in the Pneumococcal Conjugate Vaccine Era

肺炎球菌结合疫苗时代的亚太地区肺炎球菌疾病控制

• 批准号: nhmrc : 1196415
• 金额: $ 250万
• 依托单位国家: 澳大利亚
• 项目类别: Centres of Research Excellence
• 财政年份: 2020
• 资助国家: 澳大利亚
• 起止时间: 2020-01-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://researchdata.edu.au/asia-pacific-pneumococcal-vaccine-era/1779420
• 关键词: Asia; Pacific; Pneumococcal; Disease; Control

Pneumonia is one of the commonest causes of childhood death worldwide. PCV is a vaccine that prevents pneumonia but it is costly; and causes an increase in disease from strains which are not in the vaccine. Our CRE will address 2 outstanding issues: when to switch from a 3 to 2 dose PCV schedule to make it more affordable; and create new understanding of the non-vaccine strains’ impact on disease in low- and middle-income countries in the Asia-Pacific region.

肺炎是全球儿童死亡的最常见原因之一。PCV是一种预防肺炎的疫苗，但价格昂贵，并会因疫苗中未包含的菌株而导致疾病增加。我们的CRE将解决两个悬而未决的问题：何时从3剂PCV计划切换到2剂PCV计划，以使其更容易负担；以及对非疫苗毒株对亚太地区低收入和中等收入国家疾病的影响产生新的理解。